Navigation Links
Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Date:11/27/2007

ferent areas: (1) as a second-line agent for use in patients who are resistant or refractory to currently available platinums, such as SCLC, (2) as a first-line treatment in metastatic CRC patients, who cannot tolerate the toxicity profile of currently marketed platinums, (3) as an agent for use in combination chemotherapeutic regimens where platinums are currently not used, such as in the first line treatment of HRPC patients, and (4) as an oral formulation of picoplatin to provide additional convenience to patients and potential new uses in combination with orally administered cancer therapeutics.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancer, as well as a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and deve
'/>"/>

SOURCE Poniard Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets has announced the addition of the ... Disorder) Market - Forecast to 2023" report to their ... human microbiome market is segmented by application, disease, product, and ... be valued as $294 million in 2019 and is poised ... period of 2019-2023. The market is driven by growing incidences ...
(Date:9/19/2014)... 19, 2014 UBM Medica US announces that  ... community to help oncologists and other clinicians gain a ... use of targeted therapies and immunotherapies, discusses some of ... Every September, Blood Cancer Awareness ... awareness about blood cancers—helping to increase survival rates and ...
(Date:9/19/2014)...  Alere Inc. (NYSE: ALR ), a ... today in support of President Barack Obama,s ... global leader in rapid diagnostics for infectious disease, we ... address the serious threat of antibiotic resistance. We look ... initiatives to promote the development of rapid point-of-care tests ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
(Date:9/19/2014)... News) -- U.S. military troops deployed to sunny climates ... to a new study. Many returning troops ... some cases, military personnel developed blisters on their skin ... size of their moles since being deployed overseas. ... skin cancer, the study authors noted. "The past ...
(Date:9/19/2014)... News) -- Pregnant women who live in leafy, green neighborhoods ... babies, a new study suggests. Researchers analyzed data from ... expectant mothers who lived in a neighborhood with plenty of ... risk of very preterm birth (before 30 weeks) and a ... 36 weeks). Babies born to mothers who lived in ...
(Date:9/19/2014)... The U.S. Food and Drug Administration approved a new type ... a class of once-a-week injectable drugs that help manage blood ... "Trulicity is a new treatment option, which can be used ... sugar levels in the overall management of type 2 diabetes," ... Drug Evaluation II, said in an agency news release. ...
(Date:9/19/2014)... 2014 The Alliance for Bangladesh ... the National Fire Protection Association (NFPA), a recognized ... today in a Memorandum of Understanding signed by ... and other stakeholders with information, guidance and access ... health and safety of workers in ready-made garment ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 MetroMD, a leading ... the “God Particle” of human health. This therapy has grown ... making the therapy more effective, safe and dependable. It has ... them an opportunity to live a very healthy and active ... concept of HGH therapy, a senior therapist at MetroMD said, ...
Breaking Medicine News(10 mins):Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... , FRIDAY, July 15 (HealthDay News) -- In an attempt ... of governments have raised taxes on cigarettes, yet many people ... Canadian study. But the public health measure has prompted ... researchers recently reported in the International Journal of Environmental ...
... In a study, Identification of unrecognized diabetes and pre-diabetes ... issue of the Journal of Dental Research, ... that dental visits represented a chance to intervene in ... pre-diabetes who are unaware of their condition. The study ...
... sizes usually mean we eat more food, but according to ... bigger bites lead to eating lessin restaurant settings. "In ... bite-sizes on overall quantity of food consumed," write authors Arul ... Utah, Salt Lake City). The authors conducted a field ...
... HealthDay Reporter , THURSDAY, July 14 (HealthDay News) -- ... the immune system,s response to HIV, the AIDS virus, in ... a vaccine. The findings won,t have an immediate big ... do reveal how soldiers of the immune system known as ...
... five to ten percent of patients with primary ... such as headaches, seizures, confusion, difficulty swallowing and ... life-threatening form of brain invasion from cancer called ... University of California, San Diego School of Medicine ...
... This release is available in German . ... Max Planck Institute for Dynamics and Self-Organization (Gttingen, Germany), ... de Lyon (France), the University Medicine Gttingen (Germany), the ... de Nice (France) have developed a new low-energy method ...
Cached Medicine News:Health News:Cigarette Tax Unlikely to Deter Some Smokers: Report 2Health News:Dentists can identify people with undiagnosed diabetes, Columbia researchers show 2Health News:Size matters: Why do people eat less when they have big forks? 2Health News:Antibody Finding Might Help in Search for HIV Vaccine 2Health News:Novel combined therapy extends life, diminishes pain in brain cancer patients 2Health News:A 'LEAP' in controlling cardiac fibrillation 2Health News:A 'LEAP' in controlling cardiac fibrillation 3
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: